Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.
about
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyEosinophilia in Hematologic DisordersCIViC databaseResponse to imatinib mesylate in patients with hypereosinophilic syndrome.Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Eosinophilia in mast cell diseaseRecent advances in pathogenesis and management of hypereosinophilic syndromes.Recent advances in eosinophil biology.Advances in diagnosis and treatment of eosinophiliaIdiopathic hypereosinophilic syndrome: a rare cause of erythroderma.Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusClonal hypereosinophilic syndrome: two cases report in black men from sub-saharan Africa and literature reviews.The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.Therapeutic approaches to patients with hypereosinophilic syndromes.How I treat hypereosinophilic syndromes.Cardiovascular manifestations of hypereosinophilic syndromes.Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.Systemic mastocytosis: bone marrow pathology, classification, and current therapies.Modern diagnosis and treatment of primary eosinophilia.Clonality and molecular pathogenesis of mastocytosis.Chronic myeloproliferative disorders: a tyrosine kinase tale.Eosinophilia: secondary, clonal and idiopathic.Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Gastrointestinal eosinophiliaA Case of Erythroderma Secondary to Hypereosinophilia.Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Molecular diagnosis of myeloproliferative neoplasms.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.Eosinophilic diseases of the gastrointestinal tract.Cardiac Manifestations from Non-FIP1L1-PDGFRα-Associated Hypereosinophilic Syndrome in a 13-Year-Old African American Boy.World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.Clinical management of the hypereosinophilic syndromes.World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.
P2860
Q24685914-75452E75-9CD7-4D4F-A2BA-95D43CB33152Q26799611-4B162A5A-91A9-4A01-8EB7-810BD2B0F842Q27612411-C5A5576D-9081-459D-8CF5-BC7BF4D3FD47Q33402403-1632F9BA-920C-442A-B99D-C6FD6BA29A85Q33620407-A160A1F7-CC0C-4521-9CDC-AE723412CD32Q33851724-9F4EF0DB-972D-49DF-93E9-681598CA6A64Q34324934-0A5C588C-7FD9-498C-94A3-B1490CFFFD6BQ34579906-9663E660-983D-4E05-B7C6-6F88F758BBBDQ34895664-9F39DD16-EA8F-4364-9E68-4EC8CFD995CDQ34987454-8E85732D-FBAE-4E85-B4EA-9EEA9001937EQ35575492-1D102C3C-18B0-4949-8200-3FE39262F4E7Q35579165-AC1CA085-BE16-4DF7-A194-4DB59A8B3C5CQ35848279-6BD5B0EF-2AE8-4545-B8B7-D17F796A3DDEQ35857340-3E498436-CAF9-4974-B2C1-4FFF75ED7758Q36000858-35C87272-79EB-4FC7-B056-AB0BE42471E7Q36102877-D15F973A-BB0F-49D3-8102-7317EFB03733Q36141619-4070739D-6432-4AD4-B68C-FC471C81AEB4Q36182741-560A5278-EB8C-4EEC-AC54-20E81D9A0798Q36182749-E7E3C1F7-6570-49BC-B617-87AC981E5A2FQ36182754-F8EF31EF-34CC-4170-9B05-14FC60EB27CBQ36182758-49799A33-F074-402A-BB10-41552C21BE3EQ36337918-8B033AEC-E083-415A-9CAE-8875C5376E1CQ36471689-FA8C1FE6-8265-44F7-8E92-AF390DEBCCC4Q36811905-342438EA-D7E9-42C9-9801-CFF3F1147F25Q36842503-77917FEA-7B61-4936-9D44-225B7987442FQ36942155-047BEF04-C372-46DC-8507-8B755682D646Q37102781-E8C840BC-864C-40A0-B4D6-DA2A05B98C70Q37362888-9EA2F12F-1D1C-4287-8B5A-76A030F74CDDQ37379320-FFDEF079-19F8-44D8-9D4D-D58383193DA1Q37542270-A34730A5-52F7-4CA7-83B1-8FC5D4FDF7D7Q37598944-663572A7-F9B9-49EB-B2D9-34389B9DA6E6Q37755233-58841798-E841-4DE4-A6DB-C8ED2E5ECCC7Q37761380-82E31399-E295-4C21-8BBC-1C26CD06F4A6Q37803125-EF9F0E6D-1C04-4BE1-B045-F6F474AAB4AFQ37901437-7B716E08-DB6F-4427-8B98-F294ED790753Q37992835-5A8E6B33-A933-4EB3-9E0E-C6632E48CC41Q38025157-B8395C8E-3403-4D55-9866-0BF6C18968D7Q38038509-8ACF712E-56ED-4529-A1B1-207C1D3AF7A5Q38110527-C80E9179-9A03-4F4F-8DD0-FBAC6EA47775Q38131481-489B10A3-117D-4067-BDF8-167275469267
P2860
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Molecular remission and revers ...... of hypereosinophilic syndrome.
@ast
Molecular remission and revers ...... of hypereosinophilic syndrome.
@en
Molecular remission and revers ...... of hypereosinophilic syndrome.
@nl
type
label
Molecular remission and revers ...... of hypereosinophilic syndrome.
@ast
Molecular remission and revers ...... of hypereosinophilic syndrome.
@en
Molecular remission and revers ...... of hypereosinophilic syndrome.
@nl
prefLabel
Molecular remission and revers ...... of hypereosinophilic syndrome.
@ast
Molecular remission and revers ...... of hypereosinophilic syndrome.
@en
Molecular remission and revers ...... of hypereosinophilic syndrome.
@nl
P2093
P50
P3181
P1433
P1476
Molecular remission and revers ...... of hypereosinophilic syndrome.
@en
P2093
Dean D Metcalfe
Jamie Robyn
Margaret Brown
Melissa Law
Pierre Noel
P3181
P356
10.1182/BLOOD-2003-08-2798
P407
P577
2004-01-15T00:00:00Z